Discovery of proteolytically stable monocyte locomotion inhibitory factor peptide through systematic structural...

Area of Science:

• Biochemistry
• Pharmacology
• Immunology

Background:

• Osteoarthritis (OA) poses a significant clinical challenge, necessitating novel therapeutic agents.
• Monocyte locomotion inhibitory factor peptide (MLIF) exhibits anti-inflammatory properties but suffers from poor stability and short in vivo half-life.
• Structural modifications are crucial to enhance MLIF's therapeutic potential for OA.

Purpose of the Study:

• To design and synthesize novel MLIF derivatives with improved stability and preserved/enhanced anti-inflammatory activity.
• To evaluate the efficacy of these derivatives in preclinical models of osteoarthritis.

Main Methods:

• Synthesized MLIF derivatives using strategies like D-amino acid replacement and PEGylation.
• Assessed in vitro anti-inflammatory activities of the derivatives.
• Evaluated the in vivo efficacy of the lead compound in a collagenase-induced osteoarthritis (CIOA) mouse model.

Main Results:

• MLIF 30, featuring D-methionine and PEGylation of cysteine, demonstrated superior in vitro anti-inflammatory effects.
• MLIF 30 exhibited enhanced serum stability compared to native MLIF.
• In vivo studies showed MLIF 30 effectively reduced cartilage inflammation and damage in CIOA mice.

Conclusions:

• Structural optimization, particularly through D-amino acid substitution and PEGylation, significantly enhances MLIF's stability and anti-inflammatory efficacy.
• MLIF 30 represents a promising candidate for developing stable peptide therapeutics for clinical OA treatment.
• These findings advance the development of MLIF-based therapies for osteoarthritis.